Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

The survey provides insights into the safety profile of desmopressin ODT in real-clinical practice in Japan. Patients aged ≥ 75 years, those with underlying medical conditions, and those with abnormal clinical laboratory values, such as reduced renal function or a baseline serum sodium level of < 140 mmol/L, should be closely monitored for the development of hyponatremia during desmopressin treatment for nocturia due to NP.